Doseology Sciences Inc. (CSE: MOOD | OTCQB: DOSEF | FSE: VU70), a consumer product innovation company focused on oral pouch and functional stimulant product technologies, announced that it has received an additional 45-day extension from the Canadian Securities Exchange (CSE) to close its non-brokered private placement. The extension follows the Company's previous news releases dated March 30, 2026, and May 15, 2026.
Details of the Offering
The private placement (the "Offering") consists of up to 3,225,806 units (each, a "Unit") at a price of $0.62 per Unit, with the goal of raising aggregate gross proceeds of up to $2,000,000. The Company intends to use the net proceeds to advance its commercialization strategy for oral pouch products, including the acquisition of production equipment, development of a pilot manufacturing facility, initial production runs, inventory build, and marketing and distribution expansion.
Company Background
Doseology Sciences Inc. specializes in pouch-based oral stimulant and cognitive support products. The oral stimulant pouch sector is rapidly expanding as consumers seek modern, discreet alternatives to traditional delivery formats. Unlike combustible tobacco or vape products, oral stimulant pouches are smokeless and vapor-free, providing an alternative delivery method without inhalation. From a market perspective, the oral pouch category is experiencing strong global growth as consumers increasingly prioritize convenience, portability, and format innovation. The pouch sector represents one of the most dynamic and high-growth areas in modern functional consumer products.
Forward-Looking Statements
This news release contains forward-looking information (FLI) within the meaning of applicable Canadian securities laws. FLI includes statements regarding the completion and timing of the Offering; the receipt of required regulatory approvals, including approval of the CSE; the intended use of proceeds; the Company's ability to advance its commercialization strategy; and the Company's business and growth plans relating to its oral pouch and functional stimulant product technologies. FLI is based on management's current expectations, estimates, projections, and assumptions as of the date hereof. Assumptions include that the Company will be able to complete the Offering on the terms described (or at all), satisfy customary closing conditions, maintain conducive market conditions, and execute its commercialization plans as intended.
For more information, visit the Company's corporate website at www.doseology.com or its shop at www.feedthatbrain.com. On behalf of the Board of Directors, Chris Jackson, CEO and Director of Doseology Sciences Inc., can be contacted via email at hello@doseology.com or by phone at 604.908.3095.
